Corline Biomedical
16.40 SEK
-2.38 %
Less than 1K followers
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.38 %
+3.47 %
0.00 %
0.00 %
-11.59 %
+67.35 %
+70.12 %
+43.86 %
+65.80 %
Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.
Read moreMarket cap
428.58M SEK
Turnover
86.37K SEK
Revenue
7.65M
EBIT %
-192.81 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
8/5
2026
Interim report Q1'26
14/5
2026
General meeting '26
26/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Corline Biomedical AB offentliggör bokslutskommuniké för perioden januari till december 2025
CorlineCorline Biomedical stärker samarbetet med Kardium – genomför riktad emission och upptar lån från Kardium för att mångfaldiga produktionskapaciteten
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools